Sodium-Glucose Cotransporter 2 Inhibitor Use and Outcomes in Transthyretin Amyloid Cardiomyopathy

JACC Adv. 2024 Nov 15;3(12):101405. doi: 10.1016/j.jacadv.2024.101405. eCollection 2024 Dec.
No abstract available

Keywords: SGLT2 inhibitors; amyloidosis; outcomes; transthyretin amyloid cardiomyopathy.